astrazeneca glp 1 pipeline Market Overview: GLP-1 Agonists and the Obesity Market Blockbuster ambitions grow as AstraZeneca

Inflammatory bowel disease represents the most advanced clinical target, with at least one Phase II trial having examined a BPC-157-derivative compound (PL 14736) for ulcerative colitis, showing preliminary evidence of mucosal healing in human patients

It has the potential to boost performance during workouts and promote well-being while also assisting in shedding excess weight and boosting cognitive abilities

Interestingly, recent data emphasizes the role of dysfunctional circulating mediators such as resistin in the onset of obesity, IR, and cardiovascular diseases [72]

Combine it with glutathione and you've got an unbeatable tag team for restoring electrolyte balance and calming the post-party chaos in your nervous system